Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-97540 in Severe, Refractory Autoimmune Diseases (Breakfree-1)
NCT05869955Phase 1Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2023
- Primary completion
- Aug 2028
- Modality
- CAR-T Cells
- Countries
- 6
01
Overview
Phase 1, open-label, single-arm trial of BMS-986353 in systemic lupus erythematosus (SLE), idiopathic inflammatory myopathy (IIM), systemic sclerosis (SSc) and 1 more, sponsored by Bristol Myers Squibb. Primary endpoints: Adverse Events at 2 years, Serious Adverse Events at 2 years and 4 more. Started Sep 2023; status: active, not recruiting.
02
Drugs
BMS-986353
03
Conditions
systemic lupus erythematosus (SLE)idiopathic inflammatory myopathy (IIM)systemic sclerosis (SSc)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05869955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05869955.